Evidence map›Paper›PMID 41043959›Full record

ReviewBMJ global health2025

Strategies for mitigating emerging artemisinin-based antimalarial drug resistance in Rwanda: a promising approach for managing therapies in malaria-endemic countries.

Claude Mambo Muvunyi, Pierre Gashema, Aimable Mbituyumuremyi, Patrick Gad Iradukunda, Emmanuel Edwar Siddig, Jean Damascene Niyonzima, Emmanuel Hakizimana, Noella Umulisa, Abdisalan Mohamed Noor, Jules Mugabo Semahore and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BMJ global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Claude Mambo MuvunyiRwanda Biomedical Center, Kigali, Rwanda claude.muvunyi@rbc.gov.rw.ORCID 0000-0003-4180-442X
Pierre GashemaAfrica Centres for Disease Control and Prevention, Addis Ababa, Ethiopia.ORCID 0000-0001-9348-0936
Aimable MbituyumuremyiRwanda Biomedical Center, Kigali, Rwanda.
Patrick Gad IradukundaRepolicy Research Centre, Kigali, Rwanda.ORCID 0000-0002-0236-7776
Emmanuel Edwar SiddigAfrica Centres for Disease Control and Prevention, Addis Ababa, Ethiopia.ORCID 0000-0001-6314-7374
Jean Damascene NiyonzimaRwanda Biomedical Center, Kigali, Rwanda.
Emmanuel HakizimanaRwanda Biomedical Center, Kigali, Rwanda.
Noella UmulisaJhpiego Kigali, Rwanda, Kigali, Rwanda.
Abdisalan Mohamed NoorHarvard University, Cambridge, Massachusetts, USA.
Jules Mugabo SemahoreWorld Health Organization Kigali, Rwanda, Kigali, Rwanda.ORCID 0009-0003-6554-6194
Albert TuyishimeRwanda Biomedical Center, Kigali, Rwanda.
Jean de Dieu HarelimanaRwanda Biomedical Center, Kigali, Rwanda.ORCID 0000-0003-0944-5404
Jeanne UmuhireRwanda Biomedical Center, Kigali, Rwanda.
Yvan ButeraRepublic of Rwanda Ministry of Health, Kigali, Kigali City, Rwanda.
Sabin NsanzimanaRepublic of Rwanda Ministry of Health, Kigali, Kigali City, Rwanda.

Funding

World Health Organization 001
6 · The paper itself

Abstract

Malaria treatment failures associated with reduced efficacy of chloroquine (CQ) and amodiaquine (AQ) antimalarial drugs emerged in Rwanda during the 1980s, prompting the policy shift towards adopting artemisinin-based combination therapies in 2006 as an alternative. However, recent findings from malaria surveillance and therapeutic efficacy studies have revealed a countrywide increase in antimalarial drug resistance. Particularly, artemether-lumefantrine (AL) efficacy has significantly decreased, probably due to the emergence of

Indexed as

AntimalarialsArtemisininsDrug ResistanceMalaria, FalciparumPlasmodium falciparumAmodiaquineArtemether, Lumefantrine Drug CombinationDrug CombinationsEndemic DiseasesHumansMalariaMutationRwandaAmodiaquineAntimalarialsArtemether, Lumefantrine Drug CombinationartemisininArtemisininsDrug CombinationsHealth policyMalariaParasitologyTreatment

Identifiers

PMID41043959
PMCPMC12496036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.